Diabetic Nephropathy: Diagnosis, Prevention, and Treatment
Top Cited Papers
- 1 January 2005
- journal article
- review article
- Published by American Diabetes Association in Diabetes Care
- Vol. 28 (1), 164-176
- https://doi.org/10.2337/diacare.28.1.164
Abstract
Diabetic nephropathy is the leading cause of kidney disease in patients starting renal replacement therapy and affects ∼40% of type 1 and type 2 diabetic patients. It increases the risk of death, mainly from cardiovascular causes, and is defined by increased urinary albumin excretion (UAE) in the absence of other renal diseases. Diabetic nephropathy is categorized into stages: microalbuminuria (UAE >20 μg/min and ≤199 μg/min) and macroalbuminuria (UAE ≥200 μg/min). Hyperglycemia, increased blood pressure levels, and genetic predisposition are the main risk factors for the development of diabetic nephropathy. Elevated serum lipids, smoking habits, and the amount and origin of dietary protein also seem to play a role as risk factors. Screening for microalbuminuria should be performed yearly, starting 5 years after diagnosis in type 1 diabetes or earlier in the presence of puberty or poor metabolic control. In patients with type 2 diabetes, screening should be performed at diagnosis and yearly thereafter. Patients with micro- and macroalbuminuria should undergo an evaluation regarding the presence of comorbid associations, especially retinopathy and macrovascular disease. Achieving the best metabolic control (A1c 1.0 g/24 h and increased serum creatinine), using drugs with blockade effect on the renin-angiotensin-aldosterone system, and treating dyslipidemia (LDL cholesterol <100 mg/dl) are effective strategies for preventing the development of microalbuminuria, in delaying the progression to more advanced stages of nephropathy and in reducing cardiovascular mortality in patients with type 1 and type 2 diabetes.Keywords
This publication has 112 references indexed in Scilit:
- New strategies in anaemia management: ACORD (Anaemia CORrection in Diabetes) trialActa Diabetologica, 2004
- Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)Kidney International, 2003
- Effect of lipid reduction on the progression of renal disease: A meta-analysisKidney International, 2001
- Predictors of the development of microalbuminuria in patients with Type 1 diabetes mellitus: a seven‐year prospective studyDiabetic Medicine, 1999
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Apolipoprotein (a) Levels and Atherogenic Lipid Fractions in Relation to the Degree of Urinary Albumin Excretion in Type 2 Diabetes mellitusNephron, 1994
- Predicting Diabetic Nephropathy in Insulin-Dependent PatientsThe New England Journal of Medicine, 1984
- Microalbuminuria Predicts Clinical Proteinuria and Early Mortality in Maturity-Onset DiabetesThe New England Journal of Medicine, 1984
- Monitoring glomerular function in diabetic nephropathy: A prospective studyThe American Journal of Medicine, 1983
- MICROALBUMINURIA AS A PREDICTOR OF CLINICAL NEPHROPATHY IN INSULIN-DEPENDENT DIABETES MELLITUSThe Lancet, 1982